Aptevo Therapeutics price target raised to $9 from $6 at Piper Jaffray. Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating on Aptevo Therapeutics and raised his price target on Aptevo shares to $9 from $6 after Q1 prophylactic Hemophilia B therapy Ixinity sales of $4.1M beat Piper’s $3M estimate. Additionally, the firm is increasing its FY18 Ixinity sales forecast to $18M.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.